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Abstract 
Introduction: The human amniotic membrane is a highly abundant and readily available tissue that may 
be useful for regenerative medicine and cell therapy. 
Aim: To compare two previously published protocols for the isolation of human amnion mesenchymal 
stromal cells (hAMSCs), including their phenotypic characterization and in vitro potential for 
differentiation toward osteogenic, adipogenic, and chondrogenic mesodermal lineages. 
Materials and Methods: Human placentas were obtained from selected caesarean-sectioned births. Two 
different protocols (Alviano et al.1 and Soncini et al.2) for the isolation of hAMSCs were performed. After 
monolayer expansion of adherent cells from both protocols, the cells were characterized by flow 
cytometry and for multi- potentiality, as assessed by their capability to differentiate toward adipocyte-, 
osteoblast-, and chondrocyte-like cells.  
Results: Both protocols yielded hAMSCs that showed plastic adherence, fibroblast-like growth, and well-
defined human MSC markers. The cell yield and mesodermal differentiation capability of hAMSCs were 
higher in cells isolated using the Soncini protocol. 
Conclusions: Our data demonstrated the successful isolation of hAMSCs from full-term placentas using 
two published protocols. Differences between the two protocols in cell yield and in vitro differentiation 
potential are shown 
Introduction 
According to a recent proposal of the International Society for Cellular Therapy,
3
 
mesenchymal stem cells ( MSCs) are multipotent nonhematopoietic progenitors located within 
the stroma of the bone marrow and other organs that are phenotypically characterized by 
expression of several markers (e.g., CD73, CD90, and CD105) and the lack of expression of 
CD14 or CD11b, CD19 or CD79a, CD34, CD45, and HLA-DR surface molecules.
4,5
 They are 
isolated by adherence to plastic and expanded ex vivo. These cells have been shown to 
differentiate into multiple mesoderm-type lineages, including chondrocytes, osteoblasts, and 
adipocytes,
6
 and also into cell types of ectodermal (e.g., neurons) and endodermal (e.g., 
hepatocytes) origin.
7
 
MSCs have been isolated from several tissues, including bone marrow,
5
 peripheral blood,
8
 
adipose tissue,
9,10
 lung,
11
 liver,
12
 amniotic fluid,
13–15
 placenta,
6,14–16
 and umbilical cord.
17
 
Some countries have private and public stem cell banks from umbilical cord blood for 
transplant programs or personal use.
18
 
Bone marrow is the traditionally used tissue source of adult MSCs, in spite of some 
limitations. Among the most important limitations are accessibility and that the procedure 
required to obtain this kind of tissue is invasive and painful and there is a possibility of donor 
site morbidity, that the number of MSCs obtained is low, and that the potential to proliferate 
and differentiate diminishes as the donor’s age in- creases.2,17,19,20 The identification of 
alternative sources of MSCs would be beneficial for both research and therapeutic purposes. 
The human amniotic membrane (HAM) contains two different cell types from different 
embryological origins
1,21
: human amnion epithelial cells (hAECs) derived from embryonic 
ectoderm,
22
 which form a continuous monolayer that is in contact with the amniotic fluid, and 
human amnion MSCs (hAMSCs), which are derived from embryonic mesoderm
22
 and are 
sparsely distributed in the stroma underlying the amnion epithelium.
23
 Bailo et al.
24
 isolated 
and characterized amniotic and chorionic cells from human full-term placentas, which 
suggested that both cell types may represent an advantageous source of progenitor cells useful 
for cell therapy and transplantation procedures. 
Placental fetal tissues express only moderate levels of major histocompatibility complex 
class I and major histocompatibility complex class II antigens on its surface; therefore, hAECs 
and hAMSCs seem to be immune-privileged cells suitable for allotransplantation and 
regenerative medicine.
19,25
 Moreover, isolated cells have anti-inflammatory functions and 
nontumorigenicity, and do not require  the sacrifice of human embryos for their isolation, 
avoiding the current controversies associated with the use of human embryonic stem cells.
25,26
 
Given the minimal ethical and legal issues associated with HAM cell usage, further 
investigation into their functional potentials in vivo is warranted. 
Published data suggest that HAM, an abundant and readily available tissue, is a very 
attractive source of MSCs. Indeed, the HAM is becoming appreciated as an alternative to bone 
marrow for adult MSCs for regenerative medicine. This tissue is routinely discarded 
postpartum, so it is easily procured, free from ethical problems, and available in abundance, 
providing efficiency in MSC recovery with no intrusive procedures.
1
 Harvesting cells from the 
HAM is noninvasive and safe. A major advantage of cells isolated from the HAM is that they 
are harvested after birth and can be cryogenically stored to be available in a timely manner for 
patient therapy after being thawed and expanded for use in tissue engineering, cell 
transplantation, and gene therapy. 
HAM-derived cells are isolated from the full-term amnion after its manual separation from 
the chorion. Two protocols for cell isolation are described in the literature by Alviano et al.
1
 
and Soncini et al.
2
 Briefly, Alviano’s protocol involves three digestions (one mechanical and 
two enzymatic), whereas Soncini’s protocol uses only two enzymatic digestions. Both 
protocols obtain hAMSCs, but no studies have compared their efficacy. In this study, we 
compare the two protocols for isolation of hAMSCs from the HAM. We also characterized the 
phenotypes of the isolated cells and assessed their osteogenic, adipogenic, and chondrogenic 
capabilities. 
Materials and Methods 
Harvest and preparation of HAMs 
Human placentas (n = 12) from healthy donor mothers were obtained from selected 
caesarean sections at the Hospital Materno Infantil-Teresa Herrera from A Coruña, Spain. All 
the mothers gave written informed consent before collection. This study was approved by the 
Ethics Committee of Clinical Investigation of Galicia (Spain). Under stringent sterile 
conditions, the harvested placentae were placed in 199 medium (Invitrogen) with the following  
antibiotics:  cotrimoxazol 50 mg/mL (Soltrim®; Almirall-Prodesfarma S.A.), vancomycin 50 
mg/mL (Vancomicina Hospira®; Laboratorio Hospira S.L.), amykacin 50 mg/mL (Amikacina 
Normon®; Laboratorios Normon S.A.), and B amphotericin 5 mg/mL (Fungizona®; Bristol-
Myers Squibb). The HAM was carefully separated from the chorion, which was then discarded, 
and the amnion was immediately washed three to five times with 0.9% NaCl solution to 
remove blood and mucus. 
Histological analyses 
For histological  evaluation, 4-mm-thick paraffin  sections were deparaffinized in xylol, 
rehydrated in a graded series of ethanol, and stained with hematoxylin and eosin (H-E) and 
Masson’s trichrome ( MM) for HAM and chondrogenic examination and with toluidine blue 
(TB) and safranin O (SafO) for chondrogenic evaluation. 
Immunohistochemical analyses 
An immunophenotypic analysis was performed to deter- mine expression of mesenchymal 
and hematopoietic markers in hAMSCs isolated using both protocols. For immuno-
histochemical evaluations, 4-mm-thick paraffin sections were deparaffinized and hydrated, and 
then incubated with monoclonal antibodies (mAbs) to detect type II collagen (Col II) (6B3 
clone; Neomarkers) and cytokeratins (CK) 1, 2, 3, 4, 5, 6, 7, 8, 10, 13, 14, 15, 16, and 19 
(AE1/AE3 clone; Dako). To facilitate the exposure of epitopes, the sections were pretreated 
with proteinase K (Sigma-Aldrich). The peroxidase/DAB ChemMateTM DAKO EnVisionTM 
detection kit (Dako) was used to determine antigen–antibody interactions. Localization of 
MSC-derived amniotic cells by immunofluorescence was performed using the antibody FITC-
CD44 (IM7 clone; BD Pharmingen). Negative staining controls omitted the primary mAb. 
Samples were examined using an optical microscope. 
For the immunohistochemical evaluation of chondrogenesis, sections were incubated with 
antibodies to detect the presence of Col II (Neomarkers), and with a polyclonal antibody to 
detect aggrecan (C-20; Santa Cruz Biotechnology). 
Isolation and culture of hAMSCs 
Amnionic membranes were separately processed after the isolation protocols of Alviano et 
al.
1
 and Soncini et al.
2
 (Fig. 1). For Soncini’s protocol,  the HAM was cut into ~2x2 cm2 pieces 
and transferred into an enzymatic digestion buffer containing 2.4 U/mL of Dispase (Gibco) in 
phosphate-buffered saline and incubated at 37ºC for 7 min. The digested tissue was centrifuged 
and the supernatant was discarded. The tissue was then subjected to a second enzymatic 
digestion in RPMI 1640 (Lonza) culture medium containing 0.75 mg/mL type I clostridial 
collagenase (Gibco) and 20 mg/mL deoxy-ribonuclease I (DNAse I) (Sigma-Aldrich Quimica) 
for 3 h at 37ºC. After digestion, the resulting cell suspension was filtered through a sterile 70 
mm filter (BD Biosciences) and the cells were collected by centrifugation at 200g for 10 min. 
The collected cells were designated as hAMSCs. The non-digested amnion fragments were 
incubated with 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich) at 
37ºC for 2–3 min.  The cells were collected  by filtration and centrifugation, as described 
above, and designated as hAECs, which were not used in this comparative study. 
 
 
 
FIG. 1. Representative schematics of the two protocols used for 
hAMSC isolation. hAMSC, human amnion mesenchymal stromal 
cell 
For Alviano’s isolation protocol, the HAM was subjected to a full mechanical digestion. 
Pieces of amniotic membrane were minced and subjected to two enzymatic digestions. The 
first enzymatic digestion used 0.25% trypsin-EDTA for 15 min and the second was in a 
digestion buffer containing 0.25% trypsin-EDTA, 10 U/mL DNAse I, and 0.1% type I 
clostridial collagenase in Dulbecco’s modified Eagle’s medium (DMEM) (Lonza) for 5 min 
until digestion was complete. In the meanwhile the fragments were pipetted vigorously up and 
down, avoiding foaming, and the super-natant was neutralized with 5% fetal bovine serum 
(FBS; Sigma-Aldrich) in DMEM. 
The cell suspensions resulting from the digestions were centrifuged at 200g for 10 min. The 
cells were  then resuspended in DMEM with 20% FBS and 1% penicillin– streptomycin (P/E) 
(Gibco) and seeded in 162 cm
2
 culture flasks for Soncini’s and in 25 cm2 culture flasks for 
Alviano’s isolation protocol. The hAMSC cultures were grown in a humidified 5% CO2 
atmosphere at 37ºC until 70% confluent. The cells were recovered and expanded to obtain the 
appropriate number of cells for the experiments. Cells isolated from Alviano’s protocol were 
plated until fourth to fifth passage, whereas cells isolated from Soncini’s protocol were plated 
until second passage. Nonadherent cells were removed after 48 h of culture. 
Quantification of cells 
The number of hAMSCs isolated was counted using a Neubauer Chamber with cell 
viability assessed using 0.4% trypan blue dye (Sigma-Aldrich). 
Cell characterization by flow cytometry 
The hAMSCs were harvested by trypsinization, washed, and centrifuged at 300g for 8 min. 
The cells were counted and 2x105 cells were transferred to polypropylene tubes before 
fluorescence-activated cell sorting (FACS). The antibodies listed in Supplemental Table S1 
were used for these experiments. Optimal amounts for the mAbs were determined and added to 
each tube for 40 min at 4ºC in darkness. Most antibodies were conjugated with fluorescein 
isothiocyanate, phycoerithrin, or allophicocianine and were specific for the human markers 
associated with mesenchymal and hematopoietic lineages. When necessary, the cells were 
incubated for 30 min at 4ºC in darkness with  a secondary antibody to allow binding to the 
primary antibody. A control tube for each of the chromogens contained equivalent amounts of 
isotype standards. A minimum of 10,000 cell events per assay were acquired using a FACs 
Calibur flow cytometer (BD Biosciences). Data were analyzed using Cell Quest software (BD 
Biosciences). Statistical analysis was performed by the Mann–Whitney U test. The results are 
expressed as the mean ± standard deviation of the percent of positive cells. Statistical 
significance was accepted at p < 0.05. 
In vitro differentiation studies 
Adipogenesis. hAMSCs from passages 0 to 4 and human bone marrow MSCs (hBMSCs) from 
passages 2 to 3 were detached using 2xtrypsin-EDTA solution (Sigma-Aldrich) and seeded at 
1.5x105 cells/cm
2
 into a one-well chamber slide in growth medium until confluent. 
Adipogenesis was induced by culturing in Bullekit Adipogenic Differentiation Medium 
(Lonza) for 21 days following the manufacturer’s instructions. 
 
Osteogenesis. hAMSCs from passages 0 to 4 and hBMSCs from passages 2 to 3 were detached 
using 2xtrypsin-EDTA solution and seeded at 1.5x105 cells/cm
2
 into a one-well chamber slide 
in growth medium until confluent. Osteogenesis was induced by culturing for 3 weeks using 
hMSC Bullekit Osteogenic Differentiation Medium (Lonza). This culture medium was 
changed every 2–3 days. 
For adipogenic and osteogenic differentiation assays, hAMSCs grown in DMEM medium, 
containing 20% FBS and P/E, were used as controls. hBMSCs were also tested for adipogenic 
and osteogenic differentiation, with their respective controls (C hBMSCs) grown for 21 days in 
DMEM 21, as an adult MSC control. These controls were also evaluated histologically. 
Histological examinations were per- formed after cell fixation in 4% paraformaldehyde. 
To evaluate adipogenesis, the presence of cytoplasmic lipid droplets in the cultures was 
revealed by Oil-red O stain. To evaluate osteogenesis, the presence of calcium deposits in the 
cultures was determined using alizarin red stain ac- cording to a standard protocol. 
 
Chondrogenesis. Chondrogenesis was assessed by micropellet formation. hAMSCs (2.5x105 
cells/cm
2
) from passages 0 to 4 and hBMSCs (2.5x105 cells/cm
2
) from passages 2 to 3 were 
detached using trypsin-EDTA and centrifuged at 300g for 10 min. The resulting pellet was 
cultured in chondrogenic differentiation medium containing DMEM with 15% FBS. This 
medium was supplemented with 5 mg/mL ascorbic acid, 1/1000 monotioglycerol, and 1% P/E 
during the first 2 days to promote the induction of chondrogenesis. The medium was then 
replaced by DMEM with 15% knockout serum (Gibco) and 1% P/E, and supplemented with 1 
mL/mL ascorbic acid, 10 mM dexamethasone, 6 mL/mL Transferrin, 1x107 M retinoic acid, 
and 1 ng/mL of recombinant human transforming growth factor-b3 (Prospec-Tany Technogene 
Ltd.) for 21 days. The medium was changed every 2–3 days. The micropellets were embedded 
in paraffin and the presence of hyaline cartilage-characteristic molecules  was detected using 
the histological and immunohistochemical techniques. To evaluate chondrogenesis sections 
were stained with H-E, MM, TB, and Saf O. Also, immunohistochemistry studies were 
performed to detect the presence of Col II and aggrecan. 
Quantification of positive histological staining (for alizarin red, Oil-red O, and Saf O) and 
immunohitochemistry staining (for Col II and aggrecan) was performed using analiSIS® 
software (version D) (Olympus). 
Statistical analysis 
All statistical analyses were performed using SPSS 16.0 software for Windows, p-values < 
0.05 were considered statistically significant. 
Results 
Localization of HAM-derived cells 
To determine the location of HAM-derived cells, healthy HAMs (n = 4) were examined 
histologically using H-E and MM staining, and  by immunohistochemistry for Coll II and CK. 
The amnion consists of a single layer of ectodermally derived epithelium (EC), containing 
epithelial cells, (hAECs) uniformly arranged on the basement membrane (BM) (Fig. 2A, B). 
These epithelial cells are positive for the epithelial markers CK 1, 2, 3, 4, 5, 6, 7, 8, 10, 13, 14, 
15, 16, and 19 (Fig. 2C). This epithelial monolayer of cells is located on the BM, which is one 
of the thickest membranes found in any human tissue. It is a collagen-rich mesenchymal layer, 
which also contains, according to previously reported studies, MSCs (hAMSCs) (Fig. 2D). 
Healthy HAMs were also stained by immunofluorescence for CD44 stem cell marker. 
Immuno- fluorescence results confirmed that hAMSCs from BM were positive for CD44 and 
therefore that BM contains cell having stem-cell characteristics (Fig. 2E). 
Morphologic and quantification studies 
After 2 days in culture, both protocols resulted in the isolation and culture of cells attached 
to the culture flasks with fibroblast-like cell morphology (hAMSCs) (Fig. 3). Quantitative 
studies showed that Alviano’s protocol typically yielded 202,124 ± 40,521 hAMSCs per gram 
of tissue (n = 3), whereas Soncini’s protocol yielded 2,009,990 ± 2,430,783 hAMSCs per gram 
of tissue (n = 3) (Fig. 4) ( p = 0.04, Mann–Whitney U test). In addition, the latter protocol not 
only yielded a greater number of cells, but also improved the growth rate of the resultant cells 
that reached confluency of 80%–90% in a week or less. 
  
 
 
 
FIG. 2. Histological characterization of human amnion-derived cells. Sections of 
healthy human amniotic membrane (n = 4) stained with (A) H-E and (B) MM, by 
immunohistochemistry for (C) CK and  (D) Col II, and  by immunofluorescence for 
CD44 (E). BM indicates the thick basement membrane, and EC, the epithelial  cells 
from the extra-embryonic ectoderm. H-E, hematoxylin and  eosin; MM, Masson’s 
trichrome; Col II, type II collagen; CK, cytokeratins. 
 
 
 
FIG. 3. Cell morphology of hAMSCs isolated using protocols of (A) Alviano 
et al.1 and (S) Soncini et al.2 Cultures of hAMSCs isolated using Alviano’s 
protocol (A) show more fibroblast morphology than the same population 
isolated using Soncini’s protocol (B). 
  
 
 
 
FIG. 4. hAMSC yields from the protocols  f (A) Alviano et al.1 and (S) Soncini et 
al.2 Data are expressed as mean of the number of cells obtained per gram of 
amniotic tissue ± standard deviation. *p < 0.05 (Mann–Whitney U test). 
Phenotypical characterization of hAMSCs 
FACS analysis demonstrated that of the expression levels of the different markers in 
hAMSC populations obtained from both protocols, only the marker CD117 showed statistically 
significant  differences (Soncini: 22.79% vs. Alviano: 0.17%; p = 0.004) (Table 1). hAMSCs 
from both protocols lacked any hematopoietic CD34 and CD45 markers and fibroblasts, 
indicating no contamination with hematopoietic stem cells from umbilical  cord blood or 
embryonic fibroblasts. 
This phenotypic characterization demonstrated that hAMSCs have a cell surface receptor 
pattern of expression that is similar to that previously reported for BMSCs, regardless of the 
protocol used (Table 1). Interestingly, we observed that hAMSC populations obtained using 
either protocol retained their phenotypic characteristics until at least nine passages. 
 
 
 
Table 1. Analysis of Hematopoietic and Standard Adult Stem Cell Markers 
on Human Amnion Mesenchymal Stromal Cells Isolated Using Two 
Protocols 
Marker (A) % (mean ± SD) (S) % (mean ± SD) 
   
CD29  73.95 ± 29.77 82.16 ± 21.04 
CD44  60.25 ± 35.3 76.11 ± 20.16 
CD73  46.38 ± 34.9 64.34 ± 19.21 
CD90  91.31 ± 5.85 88.49 ± 11.49 
CD105  29.44 ± 32.07 31.84 ± 29.8 
CD166 52.11 ± 30.19 44.37 ± 27.72 
CD117 0.17 ± 0.14 22.79 ± 16.68a 
SSEA-4 0.8 ± 1.43 37.82 ± 40.03 
STRO-1 0.23 ± 0.005 1.29 ± 2.13 
CD34 0.13 ± 0.25 0.17 ± 0.39 
   
 
(A) Alviano et al.1 and (S) Socini et al.2 a p-Value < 0.05 ( Mann–Whitney U 
test). SD, standard deviation. 
  
In vitro differentiation potential of hAMSCs 
Isolated hAMSCs were cultured under specific conditions to perform functional 
differentiation assays. Specifically, we studied the potential of these cells to differentiate into 
adipocyte, osteoblast, and chondrocyte cell lineages. 
Adipogenic differentiation was assessed by Oil-red O staining after 21 days of culture in 
adipogenic medium (Fig. 5A, B). hAMSCs isolated with Soncini's protocol showed positive 
staining characterized by single adipocytic multivacuolar cells secreting lipid droplets. 
However, hAMSCs from Alviano's protocol produced almost no fat-containing cells. The 
percentage of Oil-red 0-positive staining cells was >50 times higher in hAMSCs isolated using 
Soncini's protocol than in hAMSCs isolated using Alviano's protocol (p=0.03, Student's t-test). 
All cells maintained in the control medium showed an absence of lipid deposits. 
 
 
 
 
 
FIG. 5. In vitro adipogenic differentiation potential of hAMSCs isolated  using protocols of (A) Alviano et al.1 and  (S) 
Soncini et al.2 hAMSCs isolated  using  two protocols, with  their respective controls (C hAMSCs), were grown for 21 
days in DMEM (DMEM 21). Adipogenic differentiation ("Dif Adipo") was determined by the presence of adipocytes 
with lipid drops detected using Oil-red O (OR-O) stain. hBMSCs were also tested for adipogenic differentiation, with 
their respective controls (C hBMSCs) grown for 21 days in DMEM 21 (A). The percentage of positive OR-0-stained 
cells is expressed as the mean ± standard deviation (B). *p < 0.05 (Student's t-test). DMEM, Dulbecco's modified 
Eagle's medium; hBMSC, human bone marrow MSC  
The osteogenic differentiation potential of hAMSCs was determined by the presence of 
calcification as shown by alizarin red stain (Fig. 6A, B). hAMSCs isolated using both protocols 
showed calcium deposition. Although the hAMSCs isolated using Soncini's protocol showed a 
percentage of alizarin red-positive-stained cells six-times higher than hAMSCs derived using 
Alviano's protocol, the difference was not statistically significant. The cells maintained in 
control medium showed practically no calcium deposits. 
 
 
 
 
 
FIG. 6. In vítro osteogenic differentiation potential of hAMSCs isolated using protocols of (A) Alviano et al. 1 and (S) 
Soncini et al2 hAMSCs isolated using two protocols, with their respective controls (C hAMSCs), were grown for 21 
days in DMEM (DMEM 21). Osteogenic differentiation ("Dif Osteo") was determined by the presence of calcium 
deposits characteristic of osteoblasts detected by alizarin red (AR) stain hBMSCs were also tested for osteogenic 
differentiation, with their respective controls (C hBMSCs) grown  for 21 days in DMEM 21. (A) The percentage of 
positive AR-stained cells is expressed as mean ± standard deviation (B). 
The chondrogenic differentiation potential of hAMSCs was determined by TB staining for 
proteoglycans, MM for collagens, and Saf O for glucosaminoglycans. The presence of Col II 
and aggrecans was detected by immunohistochemisry (Fig. 7A, B). Chondrogenesis was 
observed in all hAMSCs preparations that were isolated using both protocols. However, there 
were differences in the chondrogenic differentiation assays regarding on the protocol used for 
the isolation. In this regard, the percentage of positive staining for Coll II was statistically 
significantly higher in hAMSCs isolated using Soncini’s protocol than using the Alviano’s one. 
Coll II and proteoglycans were detected throughout the newly formed matrix, although 
immunodetection for Aggrecan was weak in most samples. 
 
 
 
Discussion 
The HAM is a thin semi-transparent tissue developed from extra-embryonic tissue 
consisting of both a fetal component, the chorionic plate, and a maternal component, the 
deciduas, composed of an epithelial monolayer, a thick BM, and an avascular stroma.
25,27,28
 
The amnion is the inner fetal layer attached to the chorionic membrane. It consists of a single 
layer of ectoderm-derived epithelium uniformly arranged on the BM. The HAM has been 
widely utilized for plastic surgery, ophthalmology, dermatology, and gynecology 
procedures.
29–33
 Preclinical and clinical studies have demonstrated multiple uses for amniotic  
membrane stem cells in tissue repair, such as corneal tissue,
34
 spinal cord injury,
35
 brain 
infarction,
36
 and Parkinson’s disease.37 
This study provides a comparison between two protocols for isolation of hAMSCs, one 
developed by Alviano et al.
1
 and one by Soncini et al.
2
 The hAMSCs, isolated using either 
protocol, showed the adherence to plastic and fibroblast-like growth observed in MSCs from 
bone marrow. Further, immunophenotypic characterization of hAMSCs demonstrated the 
presence of common, well-defined human MSC markers previously described for BMSCs, 
CD90, CD44, CD73, CD166, CD105, and CD29, with the near absence of the hematopoietic 
markers CD34 and CD45, and the lack of fibroblast markers.
38,39
 
This antigen expression pattern is consistent with data previously published for cells 
isolated from both the amnion and other regions  of the full-term  placenta.
6,23,24,38,39
 Although 
isolation and characterization of hAMSCs from the amniotic membrane have been performed 
by several independent researchers over the last few years,
1,2,7,19,39
 our results suggest that both 
Soncini’s2 and Alviano’s1 protocols yield MSCs from amniotic membrane, with some 
differences. A statistical analysis showed that the c-kit/CD117 marker was significantly ( p = 
0.004) higher in hAMSCs isolated using Soncini’s protocol, indicating that this protocol yields 
more hematopoietic progenitor cells than Alviano’s technique. Our data also indicate that 
hAMSCs in culture express such markers of undifferentiated cells as SSEA-4 and STRO-1. 
Both of these embryonic stem cell markers were present in greater quantity in hAMSCs 
isolated from Soncini’s protocol, perhaps indicating that this technique isolates cells in an 
earlier state of undifferentiation than does Alviano’s technique. 
In all HAMs analyzed, taking into account the amount of amniotic membrane used, the 
yield of hAMSCs isolated was always higher using the Soncini protocol. Therefore, Soncini’s 
protocol allowed for the isolation and expansion of a larger number of cells in a very short time 
period. This ready and rapid availability of cells is one criteria required of a source of MSCs 
for it to be considered for cell trans- plantation. 
Placental MSCs have been shown to differentiate into chondrogenic, osteogenic, 
endothelial, hepatocytic, myogenic, and neurogenic lineages, with appreciable differences in 
differentiation capability depending on the different fetal sources, placenta, chorion, or 
amnion.
1,2,7,19,22,38–43
 In this study, we performed functional differentiation studies to confirm 
that hAMSCs isolated from both compared protocols are in fact MSCs. We confirmed that 
hAMSCs isolated by both protocols can differentiate into osteocytic and adipocytic and 
chondrocytic lineages, indicating the presence of mesenchymal progenitors. 
Finally, we found differences in the results from the two isolation protocols. A larger 
number of hAMSCs were collected using Soncini’s protocol. A possible explanation could be 
that Soncini’s protocol permitted culturing of both hAMSCs and hAECs by separation, 
whereas with Alviano’s protocol both cell populations are cultured together. The effects of this 
mixed culture on cell proliferation and the isolation of MSCs are unknown. 
In conclusion, our data demonstrate the successful isolation of hAMSCs from full-term 
placentae, using two previously published protocols. The protocols differed in cell yield, and 
isolated hAMSCs from the two techniques showed differences in the in vitro potential to 
differentiate into the main mesodermal lineages, but did not differ in immunophenotype. 
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Supplemental Table S1. Antibodies Used for Flow Cytometry Cell Characterization 
Antibody Specificity Clone Source 
    
R-PE-CD29  β1 Integrin  MAR4  BD Pharmingen 
R-PE-CD34  Hemopoietic progenitor cell antigen 1 
(HPCA1) 
581  BD Pharmingen 
FITC-CD44  HCAM  IM7  BD Pharmingen 
FITC-CD45  Leukocyte common antigen (LCA)  HI30  BD Pharmingen 
PE-CD73  Ecto-5’-nucleotidase  AD2  BD Pharmingen 
PE-Cy5-CD90  Thy-1  5E10  BD Pharmingen 
FITC-CD105  Endoglin  SN6  Serotec 
APC-CD117  c-kit, SCFR  YB5.B8  BD Pharmingen 
R-PE-CD166  ALCAM  3A6  BD Pharmingen 
Fibroblast  Fibroblast-specific antigen  1B10  Sigma-Aldrich Quimica 
SSEA-4  Stage-specific embryonic antigen 4  MC-813–70  R&D Systems 
STRO-1  Stromal antigen 1  NS1-Ag4-1  Developmental Studies 
Hybridoma Bank 
    
 
 
